Table 3.
Variables n (%) or median (IQR) |
IL-6 Low levels (N = 548) | IL-6 High levels (N = 546) | p-value | TNFR1 Low levels (N = 547) | TNFR1 high levels (N = 545) | p-value |
---|---|---|---|---|---|---|
Age (years) | 74 (71–77) | 76 (72–79) | < 0.001 | 73 (71–77) | 76 (72–79) | < 0.001 |
Gender. male | 180 (32.8) | 215 (39.3) | 0.02 | 168 (30.7) | 227 (41.6) | < 0.001 |
BMI (kg/m2) | 24.8 (22.7–27.5) | 26.5 (23.7–29.3) | < 0.001 | 24.8 (22.6–27.5) | 26.5 (23.8–29.2) | < 0.001 |
MAPT group: | ||||||
PUFA + MI | 142 (25.9) | 132 (24.2) | 138 (25.2) | 135 (24.8) | ||
PUFA | 144 (26.3) | 122 (22.3) | 0.19 | 143 (26.1) | 124 (22.7) | 0.464 |
MI | 125 (22.8) | 151 (27.7) | 136 (24.9) | 138 (25.3) | ||
Control | 137 (25.0) | 141 (25.8) | 130 (23.8) | 148 (27.2) | ||
Asthma/COPD | 37 (6.7) | 40 (7.3) | 0.71 | 38 (6.9) | 38 (6.9) | 0.98 |
Stroke | 11 (2.0) | 12 (2.1) | 0.82 | 14 (2.5) | 9 (1.6) | 0.29 |
Active cancer | 21 (3.8) | 17 (3.1) | 0.51 | 18 (3.2) | 20 (3.6) | 0.73 |
IHD | 25 (4.5) | 42 (7.6) | 0.03 | 26 (4.7) | 41 (7.5) | 0.05 |
Diabetes | 39 (7.1) | 67 (12.2) | < 0.01 | 39 (7.1) | 66 (12.1) | < 0.01 |
Heart failure | 6 (1.0) | 11 (2.0) | 0.21 | 5 (0.9) | 11 (2.0) | 0.12 |
Atrial fibrillation | 14 (2.5) | 25 (4.5) | 0.07 | 19 (3.4) | 38 (6.9) | 0.99 |
Antyhypertensives | 243 (44.3) | 310 (56.7) | < 0.001 | 226 (41.3) | 323 (59.2) | < 0.001 |
CKD | 87 (15.9) | 108 (19.7) | 0.09 | 58 (10.6) | 133 (24.4) | < 0.001 |
Systolic blood pressure (mmHg) | ||||||
Baseline mean | 134.7 (126.5–143.2) | 136.4 (128.3–146.5) | < 0.01 | 134.8 (127.0–143.6) | 136.5 (127.5–146) | 0.06 |
SBPV: | ||||||
SD | 11.3 (8.3–14.1) | 11.8 (8.7–15.4) | 0.02 | 11.4 (8.3–14.7) | 11.8 (8.6–15.2) | 0.07 |
CV% | 8.3 (6.1–10.8) | 8.7 (6.5–11.0) | 0.10 | 8.4 (6.1–10.7) | 8.7 (6.5–11.1) | 0.15 |
VIM | 11.4 (8.4–14.8) | 11.9 (9.0–15.1) | 0.17 | 11.6 (8.4–14.6) | 11.7 (9.0–15.2) | 0.18 |
RSD | 17.7 (13.8–23.7) | 18.7 (14.0–25.6) | 0.06 | 17.6 (13.6–23.6) | 18.8 (14.0–25.8) | 0.02 |
ARV | 12.3 (8.6–16.6) | 13.0 (9.3–18.0) | 0.01 | 12.6 (8.6–16.6) | 12.6 (9.3–18.0) | 0.10 |
SV | 14.9 (10.5–20.1) | 15.7 (11.3–20.9) | 0.03 | 15.3 (10.6–20.2) | 15.4 (11.1–20.7) | 0.18 |
Diastolic blood pressure (mmHg) | ||||||
Baseline mean | 75.7 (70.5–81.5) | 76.3 (70.8–81.4) | 0.46 | 76.4 (71.7–81.6) | 76.0 (70.0–81.42) | 0.12 |
DBPV: | ||||||
SD | 7.3 (5.5–9.5) | 7.5 (5.6–9.9) | 0.33 | 7.4 (5.5–9.9) | 7.4 (5.6–9.7) | 0.63 |
CV% | 9.8 (7.2–12.4) | 9.7 (7.4–13.0) | 0.50 | 9.8 (7.3–12.7) | 9.7 (7.4–12.7) | 0.90 |
VIM | 7.4 (5.6–9.4) | 7.5 (5.6–9.9) | 0.42 | 7.5 (5.6–9.8) | 7.4 (5.6–9.7) | 0.78 |
RSD | 11.6 (8.7–15.1) | 12.2 (9.0–15.3) | 0.24 | 11.8 (8.9–15.1) | 11.9 (8.7–15.2) | 0.88 |
ARV | 8.1 (5.6–10.6) | 8.1 (6.0–11.2) | 0.27 | 8.1 (6.0–10.8) | 8.1 (5.6–11.0) | 0.71 |
SV | 9.8 (7.2–12.8) | 10.0 (7.4–13.3) | 0.43 | 9.8 (7.3–13.0) | 9.9 (7.0–13.0) | 0.60 |
ARV, average real variability; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, coefficient of variation; IHD, ischemic heart disease; MI, multidomain intervention; PUFA, omega-3 polyunsaturated fatty acid supplementation; RSD, residual standard deviation; SD, standard deviation; SV, successive variation; VIM, variation independent of mean
High and low levels of IL-6 and TNFR1 were identified according to the median values (2.57 pg/mL and 1141 pg/mL respectively), after removing outliers